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Abstract
The yellow fever 17D virus is attenuated and used for human vaccination. Two of its substrains, 17D-204 and 17DD, are used for vaccine
production. One of the remarkable properties of this vaccine is limited viral replication in the host but with significant dissemination of the
viral mass, yielding a robust and long-lived neutralizing antibody response. The vaccine has excellent records of efficacy and safety and is
cheap, used as a single dose, and there are well-established production methodology and quality control procedures which include the
monkey neurovirulence test (MNTV). The present study aims at a better understanding of YF 17DD virus attenuation and immunogenicity
in the MNVT with special emphasis on viremia, seroconversion, clinical and histological lesions scores, and their intrinsic variability across
the tests. Several MNVTs were performed using the secondary seed lot virus 17DD 102/84 totaling 49 rhesus monkeys. Viremia was never
higher than the accepted limits established in international requirements, and high levels of neutralizing antibodies were observed in all
animals. None of the animals showed visceral lesions. We found that the clinical scores for the same virus varied widely across the tests.
There was a direct correlation between the clinical scores in animals with clinical signs of encephalitis and a higher degree of central nervous
system (CNS) histological lesions, with an increase of lesions in areas of the CNS such as the substantia nigra, nucleus caudatus,
intumescentia cervicalis, and intumescentia ventralis. The histological scores were shown to be less prone to individual variations and had
a more homogeneous value distribution among the tests. Since 17DD 102/84 seed virus has been used for human vaccine production and
immunization for 16 years with the vaccine being safe and efficacious, it demonstrates that the observed variations across the MNVTs do
not influence its effect on humans.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The YF 17D virus, including the two main substrains in
use nowadays, 17D-204 and 17DD, is one of the most
successful vaccines developed to date. There is a well-
defined and efficient production methodology and strict
quality control including monkey neurovirulence test
(MNTV); it induces long-lasting immunity, is cheap, and is
used as a single dose. Since 1945, the use of YF 17D virus
has been estimated to be over 200 million doses with an
excellent record of safety. Only 21 cases of postvaccinal
encephalitis have been recorded with incidence predomi-
nantly in very young infants (WHO, 1993; Monath, 1999).
More recently, cases of severe adverse events associated
with the 17D vaccine have been reported (Chan et al., 2001;
Martin et al., 2001; Vasconcelos et al., 2001). Earlier, Jen-
nings et al. (1994) found that virus recovered from one fatal
case contained two amino acid changes in the envelope
glycoprotein gene and had an increased neurovirulence in
animals. However, virus isolates from two other fatal cases
demonstrated genetic stability and attenuated phenotype
(Galler et al., 2001), suggesting that some peculiarities of
the health status of a host could be responsible for such rare
events.
The MNVT is used for control of attenuation of YF
vaccine viruses (Levenbook et al., 1987; WHO, 1998). Any
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new virus seed or new vaccine(s) lots must be tested for
monkey neurovirulence before its administration to humans.
In this MNVT a group of monkeys is required to be used
with a well-known vaccine virus that will serve as the upper
limits for the parameters observed, such as viremia, sero-
conversion, type, duration, and magnitude of clinical signs
and the histological scores derived from several areas of the
central nervous system (CNS).
The history of YF 17DD virus in Brazil has been well
documented (Fox and Penna, 1943; Post et al., 2001). This
strain was brought in Brazil as vaccine NY41, which cor-
responded to subculture 230 of the 17DD substrain. Seed lot
17DD was received from a low passage of this substrain,
17DD EPlow, and represents one of its subcultures, used for
vaccine production (secondary seed lot). The 17DD EPlow
virus remained as the main substrain for vaccine production
given its attenuation for humans (Fox et al., 1942) and
nonhuman primates (Fox and Penna, 1943) as well as its
immunogenicity (Fox and Cabral, 1943; Fox et al., 1948).
We have used the YF 17DD 102/84 virus as reference in
several MNVTs to examine the attenuation of experimental
YF vaccine viruses. Here we describe the neurovirulence of
the YF 17DD 102/84 virus for rhesus monkeys observed in
these tests.
Results
Behavior of YF 17DD 102/84 in the neurovirulence test
in monkeys
Viremia
Table 1 shows that mean viremia values were in the
range of 1.30 to 2.14 log10 PFU/mL with minimal and
maximal individual titers of 0.90 to 2.70 log10 plaque-
forming units (PFU)/mL. In test F, three animals were
inoculated and bled for nine consecutive days postinocula-
tion (p.i.) for viremia analysis: peak viremia occurred on the
fourth and fifth days p.i. Only 2 of 49 monkeys displayed
viremia on the sixth day but 25 showed viremia on the
second and fourth days p.i. In general, the viremic period
was between days 2 and 5 p.i., with an average peak titer of
1.30 log10 PFU/mL.
The definition put forward by WHO (1998) of viscerot-
ropism of 17D virus limits the amount of circulating virus to
below 500 mouse LD50/0.03 mL for all (10 of 10) sera and
100 LD50/0.03 mL in 1 of 10 monkey sera at 1:10 dilu-
tion. In this context, the highest mean peak titer observed in
all tests (B–F) was 2.14 log10 PFU/mL that corresponds to
1.12 LD50/0.03 mL, consequently well below the estab-
lished limits. For comparison, this range of titers is similar
to those observed for YF 17D-204 virus or recombinants
thereof expressing the prM/E genes of Japanese encephalitis
or dengue type viruses (Monath et al., 2000, 2002; Guira-
khoo et al., 2000, 2002).
The neutralizing antibody titer showed a statistically
significant linear correlation with the amount of circulating
virus (0.76; P  0.004). Table 2 shows the extremely
variable antibody titers measured for 12 monkeys with peak
Table 1
Viremia mean peak titers in monkeys inoculated with YF 17DD 102/84
virus
Testa Mean peak titers
log10 PFU/mL (SD)
Range
B 1.66(0.48) 1.22–2.51
C 1.93(0.40) 1.40–2.48
D 2.11(0.24) 1.70–2.51
E 2.14(0.32) 1.70–2.70
F 1.30(0.40) 0.90–1.50
For comparison:
YF 17D-204b 2.63(0.40) 1.80–3.00
YF 17D-JEc 2.10(0.20) 1.30–2.30
YF 17D-den-2d 1.34(0.40) 0.70–1.50
a There was no detectable viremia in test A.
b YF 17D-204 (Monath et al., 2000).
c YF 17D-chimeric japanese encephalitis (Monath et al., 2000).
d YF 17D-chimeric dengue type 2 (Guirakhoo et al., 2000).
Table 2
Correlation of viremia, neutralizing antibody response, clinical and histological scores in monkeys inoculated with YF 17DD 102/84 virus
Animals Titer (2.30 log10
PFU/mL)
Neutralizing
antibody titers
Clinical score Combined histological
score
01 2.51 1280 0.00 0.97
Q1 2.44 37153 0.57 0.82
Q46 2.48 38019 0.34 1.33
R17 2.30 12589 0.27 0.61
R63 2.40 49564 0.37 1.47
R65 2.48 51501 0.20 0.88
S12 2.40 93415 0.70 1.81
S17 2.51 64565 0.27 1.34
S27 2.70 218408 0.10 0.53
S44 2.35 35930 0.17 1.22
S57 2.36 13400 0.00 0.42
S61 2.35 239 0.00 1.09
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viremia titers equal or above 2.30 log10 PFU/mL, suggest-
ing that even with limited viral replication (as evidenced by
circulating virus) there is enough viral antigen for eliciting
an effective neutralizing antibody response. It is noteworthy
that cynomolgus monkeys inoculated intracerebrally (i.c.)
had measurable neutralizing antibody titers 6 years after
receiving the 17D virus (M.Simo˜es, A. Travassos da Rosa,
and R. Galler, unpublished data). In the case of humans
inoculated by the subcutaneous route, as recommended by
WHO (1998), the viremia titers are limited and nondetect-
able in the majority of the vaccinees (Camacho et al.,
unpublished data). However the efficacy is high (90%);
immunity is long-lasting, and antibodies may persist for
over 30 years (Poland et al., 1981). Therefore revaccination
is recommended every 10 years (WHO, 1993).
Animals with higher viremia (2.30 log10 PFU/mL; n
12; Table 2) show a tendency of an early onset of fever (7.4
days) as compared to animals with lower viremia (2.30
log10 PFU/mL; n  37; 8.4 days). This difference is statis-
tically significant (t  1.74; P  0.04). The duration of
fever does not differ significantly between the two groups
(3.5 versus 3.7 days; Kolmogorov–Smirnov test, P  0.98).
It is of interest that 3 of 12 animals, which had the highest
viremias, did not display clinical manifestations (Table 2),
whereas the other 9 monkeys had clinical scores ranging
from 0.10 to 0.70. The same holds for the combined histo-
logical score as the 12 animals that presented higher viremia
(2.30 log10 PFU/mL) presented a combined score of 1.04
(SD  0.41). The other group (n  37) with lower viremia
(2.30 log10 PFU/mL) had a combined histological score of
1.11 (SD  0.36). These differences were not statistically
significant (t  0.53, P  0.60).
Immunogenicity
All animals developed measurable levels of neutralizing
antibodies, evaluated by the plaque reduction test with val-
ues ranging from 239 to 218,408 (Table 2).
Fever
The data for rectal temperature of all 49 monkeys are
displayed in Fig. 1 as a graph and represented by the
average temperature of the number of monkeys per group
per day. There is a tendency for the animals to have fever
between days 8 and 11 p.i.
Clinical scores
Fig. 1 shows daily mean clinical scores. Clinical signs
were observed from the 6th day p.i. until the 16th day. From
this day on, some animals did not improve and remained
with clinical signs until the end of the observation period
(30 days). Sixteen monkeys developed some signs of en-
cephalitis with clinical scores of 3 or more for at least 1 day
(Table 3), whereas only five of them had at least 1 day of
higher viremia (2.30 log10 PFU/mL). Clinical signs were
more prevalent after viremia waned and it overlaps with the
development of fever. The most severe signs usually took
place after defervescence. The clinical scores varied from 0
to 2.67, resulting in an average score of 0.32 (SD  0.56).
Two monkeys with the highest scores died. The coefficient
of variability for a sample is defined by the standard devi-
ation over the average (SD/x), which must be between 0.2
and 0.3 (Armitage and Berry, 1994). For the tests above this
relation is 1.75, an extremely high value indicating variable
data and rendering it difficult to apply any statistical anal-
ysis. This variability is evident in all experiments in which
Fig. 1. Febrile reactions (°C) and mean daily clinical scores in monkeys inoculated with YF 17DD 102/84 virus.
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there is always at least one animal that extrapolates the
group average.
Histological lesions: scores and distribution within
different areas of the CNS
All 49 animals developed histological lesions in the
CNS. The same was demonstrated for other 17D viruses
(Fox and Penna, 1943; Nathanson et al., 1966; Levenbook et
al., 1987; Marchevsky et al., 1995). The combined histo-
logical scores in our study varied from 0.34 to 1.82 (mean
 1.09; SD  0.37). The coefficient of variability (SD/x) is
0.33, allowing the application of statistical tests as recom-
mended by internationally accepted guidelines (WHO,
1998).
The different anatomical structures of the CNS are clas-
sified as target, discriminatory, and spared areas (Leven-
book et al., 1987), depending on the degree of tissue in-
volvement. The spared areas have indeed minimal lesions as
compared to the target and discriminator areas. Among the
spared areas mostly affected the nucleus ruber showed
grade 1 in 12 structures of 98 observed. Among the dis-
criminator areas, the most affected were the nucleus cau-
datus, globus pallidus, and putamen, in which 45, 29, and
38 structures (of 98 examined) presented grade 2. The target
area (substantia nigra) showed grade 2 in 55 of 98 hemisec-
tions.
Histological analysis of animals with clinical encephalitis
Tables 3 and 4 show the correlation between the obser-
vation of clinical encephalitis and the extent of histological
lesions in the target and discriminator areas. The average
combined histological score for the group with encephalitis
was 1.31 (SD  0.38), whereas the group without signs of
encephalitis showed an average score of 0.98 (SD  0.30).
The use of one-sided t test on these averages demonstrated
that they are significantly different (P  0.04). Moreover
the use of linear regression analysis also suggested that this
correlation is real (Pearson coefficient  0.41; P  0.01).
Table 5, which was derived from Tables 3 and 4, shows
that animals from the group with clinical encephalitis do not
differ from animals without when we considered the total
number of grades 1 and 2 in the different structures of the
target and discriminatory areas. However, if we consider the
percentage of structures in both areas that displayed grades
1 and 2, it is apparent that certain structures are more
relevant. We observed that animals with clinical signs of
encephalitis, as compared to the group without, had in-
creased grade 2 lesions in the target (substantia nigra) and
some discriminator areas (nucleus caudatus, intumescentia
cervicalis, and ventralis). These are probably the areas most
likely to be involved in clinical manifestations in animals
inoculated i.c. with YF 17DD 102/84 virus.
Discussion
Monkeys inoculated subcutaneously with wild-type YF
virus developed viremia between days 2 and 6 p.i. with
Table 4
Clinical and histological scores of animals without clinical signs
of encephalitis
Monkey Clinical score Histological scores
Discriminator
areas
Target area Combined
01 0.00 0.45 1.50 0.97
02 0.00 0.55 1.00 0.77
03 0.00 0.83 2.00 1.41
04 0.00 0.41 2.00 1.20
05 0.00 1.36 2.00 1.18
16 0.00 0.50 1.00 1.00
17 0.00 0.57 1.00 0.78
18 0.17 0.86 1.50 1.18
20 0.00 0.39 1.00 0.70
Q30 0.30 0.69 2.00 1.34
Q46 0.34 0.67 2.00 1.33
R1 0.03 0.57 2.00 1.28
R7 0.00 0.09 1.00 0.54
R24 0.03 0.35 1.50 0.92
R25 0.20 0.63 2.00 1.31
Q28 1.20 0.76 1.00 0.88
R65 0.20 0.76 1.00 0.88
R31 0.14 0.63 2.00 1.31
R39 0.17 0.58 1.00 0.80
R66 0.47 1.09 1.50 1.30
S27 0.10 0.07 1.00 0.53
S28 0.24 0.54 2.00 1.27
S57 0.00 0.35 0.50 0.42
S61 0.00 0.69 1.50 1.09
Mean (SD) 0.11(0.23) — — 0.98 (0.30)
Table 3
Clinical and histological scores of animals with clinical signs
of encephalitis
Monkey Clinical score Histological scores
Discriminator
areas
Target area Combined
19 2.67 1.14 2.50 1.82
Q11 0.57 0.64 1.00 0.82
Q33 0.94 0.53 1.00 0.76
9 0.74 0.72 2.00 1.36
R6 2.60 1.25 2.00 1.62
R17 0.27 0.73 0.50 0.61
R37 0.24 1.09 2.00 1.54
R63 0.37 0.94 2.00 1.47
R67 0.34 1.00 2.00 1.50
S12 0.70 1.62 2.00 1.81
S17 0.27 0.68 2.00 1.34
S20 0.50 1.37 2.00 1.69
S37 0.37 0.54 2.00 1.27
S15 0.87 0.60 1.00 0.80
S44 0.17 0.44 2.00 1.22
S67 0.35 0.64 2.00 1.32
Mean (SD) 0.75(0.77) — — 1.31(0.38)
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titers near 8.0 log10 PFU/mL (Monath et al., 1981). We have
recently inoculated 14 rhesus monkeys by the subcutaneous
route with YF 17DD 102/84 virus, and 4 of the animals
showed viremia with the highest titer only 2.43 log10
PFU/mL (data not shown). YF 17DD 102/84 virus inocu-
lated i.c. penetrated the blood-brain barrier and was found in
the bloodstream of most rhesus monkeys. The highest peak
titers of peripheral viremias observed for 49 rhesus mon-
keys inoculated i.c. was 2.70 log10 PFU/mL. Galler et al.
(2001) have shown that monkeys inoculated intrahepatically
with 17DD 102/84 virus also displayed limited viremia
(highest peak titer of 1.98 log10 PFU/mL). Altogether, these
observations suggest that YF virus attenuation implies in its
limited capacity of replication in monkeys, regardless of the
inoculation route.
We have examined histologically several extraneural or-
gans of all rhesus monkeys from all six tests. Those organs
included liver, heart, kidneys, spleen, and adrenals since
they are often involved in YF pathogenesis and other non-
related organs (tongue, esophagus, lungs, stomach, pan-
creas, gut, and tonsils). All of them showed no lesions (data
not shown). The liver of the monkeys from test F was tested
by virus isolation and immunostaining, and no viral antigen
was detected. Clinical chemistry analysis of serum amino-
transferases (AST/ALT) and several other markers, as well
as hematological analysis with total and differential white
blood cell counts, did not suggest any alteration in the
condition of the inoculated animals (Galler et al., 2001).
These data further support the attenuation of YF 17DD
102/84 virus.
Recently, Vasconcelos et al. (2001), Martin et al. (2001),
and Chan et al. (2001) described a total of seven human
cases with multiple organ failure, including liver and kid-
neys, after vaccination with 17D virus. These are very rare
manifestations and constitute the first cases of fatal adverse
events of this nature amid the estimated 400 million vacci-
nees to date. Previous adverse reactions to YF 17D vacci-
nation involved exclusively the central nervous system (Fox
et al., 1942; WHO, 1993; Monath, 1999). Galler et al.
(2001) have shown that virus derived from two of the cases
had identical genomic sequences as 17DD 102/84 seed lot
virus from which the vaccine batches had been derived.
Further inoculation of rhesus monkeys through the intrace-
rebral and intrahepatic routes failed to reveal any pheno-
typic changes, suggesting that some as yet unknown host
factors were involved in the exquisite sensitivity to the
vaccine. It may be relevant that usually one animal in each
group of 10 develops more severe forms of encephalitis
following i.c. inoculation of YF 17DD 102/84 virus. The
higher frequency in the MNVT may be due to the intrace-
rebral route of inoculation.
It would be of interest to see whether two main substrains
of YF 17D virus, used for vaccine production and human
immunization, the 17DD and the 17D-204 viruses, differ in
their attenuation in the MNVTs as genetic differences have
been noted between them (Monath et al., 1983; Ryman et
al., 1997; Galler et al., 1998). Data on YF 17D-204 virus
neurovirulence for rhesus monkeys are available from the
literature (Levenbook et al., 1987; Monath et al., 2000).
Since these tests with 17D-204 viruses were carried out
following the WHO guidelines, they are comparable to ours.
The comparison between both substrains of YF 17D virus
was limited to the combined histological scores since they
are less prone to individual variations. We have used meta-
analysis to compare both substrains. This is an important
statistical tool that allows the comparison of different stud-
ies (Hedges and Olkin, 1985). In the 95% confidence inter-
val, animals inoculated with YF 17DD 102/84 (n  49) had
values ranging from 0.98 to 1.20 with an average of 1.09,
whereas the animals inoculated with YF 17D-204 (n 106)
displayed values from 0.40 to 0.90 (mean 0.65). As the
average for virus YF 17DD 102/84 lies outside the 95%
confidence interval established for YF 17D-204 virus and
vice versa, there is a suggestion that the YF 17DD 102/84
virus presents a higher degree of neurovirulence in the
MNVT than the 17D-204 virus. The molecular basis for this
difference remains undetermined as these viruses differ at
several positions in the genome (Galler et al., 1998, 2001;
Pugachev et al., 2002). Since both strains have been used for
decades in human immunization with similar efficacy and
safety, the observed differences, genetic or phenotypic, are
not relevant concerning human vaccination.
Table 5
Comparison of the frequency of histological lesions in the CNS of animals with or without clinical signs of encephalitis
Monkeys/CNS structure Substantia
nigra
N. caudatus G. pallidus Putamen N. ant./med.
thalami.
N. ventrolat.
thalami
Intumescentia
cervicalis.
Intumescentia
ventralis
With signs of
encephalitis (n  16)
Grade 2 71.8 65.6 43.7 40.6 31.2 18.7 25.0 31.2
Grade 1 21.8 25.0 50 53.1 46.8 50.0 37.5 40.6
Without signs of
encephalitisa (n  24)
Grade 2 52.0 37.5 31.2 33.3 20.8 8.3 4.1 6.2
Grade 1 45.8 50.0 66.6 58.3 47.9 39.5 47.9 35.4
a The six animals from test A and three animals from test F did not show any clinical signs and were not included.
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Materials and methods
Virus
Yellow fever secondary seed lot (YFV 17DD 102/84)
was used for vaccine production at Bio-Manguinhos from
1984 through 2001 with an estimate of 373 million doses
produced. It was prepared with a titer of 6.47 log10
PFU/mL. The virus contained in the original vial was re-
constituted in 0.5 mL of sterile water as specified by the
manufacturer (Bio-Manguinhos, Rio de Janeiro, Brazil). All
animals received approximately 25,000 LD50 (mouse 50%
lethal dose, MLD50) according to the WHO guidelines that
recommend doses between 5000 and 50,000 LD50. The
MLD50 was established for YF 17DD vaccine virus at
Bio-Manguinhos by inoculating groups of mice with differ-
ent dilutions of the virus and estimating the 50% mortality
(Reed and Munch). The ratio between MLD50 and plaque
forming units in Vero cells culture is 0.70 log10, meaning
that the PFU titer is five times higher. The viral inocula were
back titrated by plaque assay on Vero cells.
Cells
Vero cells (ATCC, CCL 81) were maintained in Medium
199 with Earle’s salts (E199), buffered with sodium bicar-
bonate, and supplemented with 10% fetal bovine serum
(FBS) and antibiotics.
Inoculation of monkeys
A total of 49 captive-bred healthy rhesus monkeys (Ma-
caca mulatta), 37 male and 12 female, weighing 1440 to
10,300 g, were obtained from the Primatology Division
(CECAL/FIOCRUZ, Rio de Janeiro/Brazil). All monkeys
were shown to be free of YF neutralizing antibodies by
plaque reduction neutralization assay before inoculation.
Monkeys for the study were combined from six groups,
designated as A to F (Table 1). Each animal was kept in a
separate cage under controlled environmental conditions
(temperature 20–22°C, relative humidity 60%, and 12 h
of artificial light and 12 h of darkness). Animals were fed
twice daily with monkey chow supplemented with fresh
fruits and allowed water ad libitum.
Monkeys were anesthetized by intramuscular injection of
ketamine hydrochloride (20 mg/kg body weight) and inoc-
ulated with 0.25 mL of viral suspension by the intracerebral
route into the right frontal cortex.
Viremia
Blood samples for the determination of viremia were
collected on days 2, 4, and 6 after inoculation in tests A
through E and from 1 through 9 in test F. Serial dilutions
(1:3, 1:30, 1:300) of each monkey serum were titrated by
plaque assay on Vero cell monolayers (105 cells/cm2) with
3.5% carboxymethylcellulose as overlay in six-well plates.
One hundred microliters of virus suspension was inoculated
per well with four wells per dilution.
Seroconversion
Antibody titers were determined by a 50% plaque reduc-
tion test on Vero cells. The plaque reduction neutralization
test (PRNT) was conducted in serial twofold dilutions start-
ing at 1:16 in six-well tissue culture plates, with 30 PFU/
well. A positive monkey serum sample with yellow fever
antibody content calibrated by a WHO International Refer-
ence Preparation was included in each set of test. Dilutions
of both virus and samples were performed in 199 medium
containing 5% fetal bovine serum. After incubation at room
temperature for 1 h, 50 L of a suspension of Vero cells in
199 medium in a density of 1.6  105 cells was added to
each well and the plates were incubated at 37°C in 5% CO2
atmosphere for 3 h. The medium was discarded and re-
placed with 199 medium with 5% fetal bovine serum con-
taining 3.5% carboxymethyl cellulose. After incubation at
37°C in 5% CO2 atmosphere for 7 days, the monolayers
were fixed with formalin and stained with crystal violet and
plaques were counted. The log10 dilution of the test and
standard serum which reduced the plaque numbers by 50%
relative to the virus control was determined by linear re-
gression. The mean antibody titer at the 50% end point of
the standard serum was then calculated and added to the
log10 end point for each sample to provide the final value in
log10 mIU/mL.
Clinical observation
Monkeys were observed for 30 days and rectal temper-
ature was recorded. Temperature equal to or greater than
40.0°C was considered elevated. Records of clinical obser-
vation were obtained using the WHO (1998) recommended
scores: grade 1  rough coat, not eating; grade 2  high-
pitched voice, inactive, slow moving; grade 3  shaky
movements, tremors, uncoordinated movement, limb weak-
ness; grade 4  inability to stand, limb paralysis, or death.
A monkey that died received the score “4” from the day of
death until day 30.
Necropsy and histological examination
All animals were submitted to full necropsy at the end of
the observation period. They were euthanized by exsangui-
nation under deep anaesthesia. Serum samples were col-
lected to determine anti-YFV antibodies by plaque-reduc-
tion neutralization assay.
Five levels of the brain and six levels of each of the
lumbar and cervical enlargements were examined. Brain
levels included block I, the corpus striatum at the level of
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the optic chiasma; block II, the thalamus at the level of the
mamillary bodies; block III, the mesencephalon at the level
of the superior colliculi; block IV, the pons and cerebellum
at the level of the anterior olives border; block V, the
medulla oblongata at the middle of the inferior olives
(WHO, 1998).
Fig. 2. Histological lesions in the substantia nigra of rhesus monkeys inoculated with YF 17DD 102/84 virus. All panels are 160 magnifications. All
sections are 6 micra and stained with gallocyanin. (A) Grade 0: normal neurons without evidence of inflammation or perivascular infiltration (arrow). (B)
Grade 1: no neuronal involvement and minimal perivascular cuff (arrows) with few layers of inflammatory cells. (C) Grade 2: perivascular cuffs (arrow) with
densely packed layers of mononuclear inflammatory cells and an increase in the number of glial cells over the affected area. (D) Grade 3: multiple focal
infiltrates and perivascular cuff (arrow), reduction in the size and number of neuronal cells, and evidence of neuronophagia (arrowhead).
61R.S. Marchevsky et al. / Virology 316 (2003) 55–63
Numerical scores were given to each hemisection of the
cord and to structures in each hemisection of the brain.
Lesions were scored according to the following grading
system: 1, (minimal), one to three small, focal inflammatory
infiltrates, a few neurons may be changed or lost; 2, (mod-
erate), more extensive focal inflammatory infiltrates, neuro-
nal changes, or loss affects no more than one-third of neu-
rons; 3, (severe), neuronal changes or loss of 33–90% of
neurons, with moderate focal or diffuse inflammatory infil-
tration; 4, (overwhelming), more than 90% of neurons are
changed or lost, with variable, but frequently severe, inflam-
matory infiltration. Fig. 2 shows a panel of histological
sections representative of grades 0–3 in the substantia nigra
of rhesus monkeys inoculated i.c. with YF17DD 102/84
virus.
Three separate scores were calculated for each monkey:
discriminator areas only, target areas only, and discrimina-
tor plus target areas (Levenbook et al., 1987). The target
area is the substantia nigra, whereas the discriminator areas
include the caudate nucleus, globus pallidus, putamen, an-
terior and medial thalamic nucleus, lateral thalamic nucleus,
and cervical and lumbar enlargements. Both discriminator
and combined group mean scores were be taken into ac-
count for decision making on vaccine acceptability (WHO,
1998).
Statistical analysis
Means and standard deviations were calculated for the
onset and duration of fever, viremia peak titers, seroconver-
sion, and clinical and combined histological scores. Vari-
ables were compared for animals with high and low levels
of viremia and for animals with and without clinical en-
cephalitis. Student t-test was used for comparing means.
When there was a suggestion that data were asymetrical or
variances were not homogeneous, data transformation was
carried out. If this procedure was not successful, nonpara-
metric statistical tests were performed (Kolmogorov–Smi-
mov test). Differences were considered as statistically sig-
nificant if P value was 0.05 or less. P values between 0.06
and 0.10 were considered as borderline. Pearson correlation
coefficient was used to evaluate the presence of linear cor-
relation between continuous variables. Meta-analysis tech-
nique was used for combining findings from different ex-
periments carried out under the same conditions.
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